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ABSTRACT Six quality-control laboratories in 4 countries independently bioassayed aliquots of a flowable
formulation of Bacillus thuringiensis var. israelensis (B.r.l.) against the international standard powder IPS-82.
All laboratories substantially followed World Health Organization or U.S. Department of Agriculture standard
protocols. Significant differences were found in resulting potency values between laboratories. Factors that may
have influenced results, such as age, stage, and strain of larvae used, amount and type of food provided to
larvae, and processing of samples were examined. Use of different rearing temperatures, different strains of
Aedes aegypti L., or late 3rd instars vs. the recommended early 4th instars did not explain the inconsistencies.
The slope of the dose-response curve of the IPS-82 powder was influenced by particle size, which varied with
the nature and duration of sample homogenization. Laboratories using low-intensity processing obtained a greater
slope in the dose-response curve for the flowable product than for the powder standard. The type and quantity
of food provided to larvae affected susceptibility. Larvae fed an excess of protein-rich food became 4th instars
in 3 days and were less susceptible to B.t.i. than those fed smaller quantities of carbohydrate-rich food that
became 4th instars in 5-7 days. Overall, deviations from standard protocols with regard to larval stage, holding
temperature, and lighting regime may not be as important as differences in sample processing and pretest rearing
conditions. The need to improve standardization in these areas, which are not clearly specified in current pro-
tocols, is discussed.
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INTRODUCTION
Bacillus thuringiensis var. israelensls (B.r.l.) is a
spore-forming bacterium that produces a proteina-
ceous incrustation in a crystalliferous body during
sporulation. The crystal consists of at least 4 pro-
tein protoxins. Upon digestion by an insect larva
having a sufficiently high midgut pH, the dissolved
protoxins are enzymatically converted to the toxins
that work more or less in concert (Federici and Wu
1994). lt the larva is a mosquito or other suscep-
tible dipteran species, the toxins attach to receptors
in the midgut membrane and initiate a process end-
ing in cell lysis. An individual insect dies when a
sufficient amount of toxin is ingested and activated
(Federici et al. 1990). Ultimately, the mortality in
a population of susceptible larvae is dependent
upon the quality and quantity of toxin ingested.
This characteristic of dose-dependence is used
for determining the potency of a product based on
B.t.i. A standard method has been developed in
which a product of unknown potency is tested in
parallel with a reference standard of known poten-
cy. A series of dilutions are made of both products,
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early 4th-instar mosquito larvae are exposed to the
dilutions, and mortality is read after 24 h (de Barjac
and Larget-Thiery 1984, Mclaughlin et al. 1984,
de Barjac 1985). The potency of the nnknown can
be calculated from the potency of the reference
standard using a mortality difference ratio. In prac-
tice. we use the ratio of median lethal concentration
(LC.o) values determined from log-probit-trans-
formed dose-mortality data. The LCro values are
most accurately determined when a series of dilu-
tions result in a distribution of mortalities both
above and below 5OVo, but not reaching the ex-
tremes of 0 or 10O7o.
Theoretically, calculation of the potency of the
unknown is not valid unless the unknown and the
reference standard form parallel dose-mortality
curves. However, the standard bioassay protocol
does not stipulate a test of parallelism, and dose-
mortality curves are often not parallel. Neverthe-
less, potency values are always provided on the la-
bels of commercial B.t i. products.
Certain other test parameters can significantly af-
fect potency determinations of B.r.i. products. For
instance, Skovmand et al. (1997) showed that the
slope of the dose-response curve is inversely pro-
portional to the size of particles in a formulation.
When the aggregates of spores were nondestruc-
tively made smaller, slope increased, and vice ver-
sa. Among the commercially available products,
most flowables have a small median particle size
compared to powders. The international standard
IPS-82 from Institut Pasteur (Paris, France) is a
powder having a bimodal particle size distribution
with peaks around 1.5 and 15 pm. In this study, we
compare IPS-82 with a flowable formulation having
a unimodal particle size distribution with a peak
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around 1.5 pm (Skovmand et al. 1997). Also, by
having several laboratories bioassay aliquots of the
same 2 samples, we can determine the extent of
interlaboratory variation. The results will shed light
on the value that the end user can attach to label
potency values and may lead to more refined pro-
tocols to reduce variabilitv.
MATERIALS AND METHODS
The following laboratories participated in this
study: the quality control laboratory of Novo-Nor-
disk Plant Protection Division, Bagsvaerd, Den-
mark; the Institut Pasteur, Unit6 des Bact6ries En-
tomopathog6nes, Paris, France; ElD-Mediterannde,
Montpellier, France; ORSTOM-Bondy, Paris,
France; KABS, Waldsee, Germany, in cooperation
with the National Institute of Public Health, Praha,
Czech Republic; and Benzon Research, Carlisle,
PA, USA. These laboratories routinely perform
large numbers of B.r.i. potency bioassays.
Mosquito larvae: Aedes aegyptl L. larvae were
used by all laboratories. The laboratories at EID,
ORSTOM, KABS, and Institut Pasteur used the
strain bora bora as recommended in the World
Health Organization (WHO) protocol written by the
latter laboratory. The laboratory at Novo-Nordisk
used a strain originating from The London School
of Hygiene and Tropical Medicine (London, United
Kingdom). Benzon Research used a strain that orig-
inated from Gainesville, FL. All laboratories used
early 4th instars, except EID, which used either late
3rd instars or early 4th instars that were 24 h older.
Fifty to 100 larvae were used per concentration for
each replicate (Table 1).
Rearing: The standard protocols provide no
guidelines for rearing conditions prior to bioassay,
and many types of food were used, such as desic-
cated liver powder, aquarium fish flakes, and dog
and cat food pellets, either powdered or introduced
whole into the water for gradual dissolution.
At Novo-Nordisk, additional tests were per-
formed to determine the influence of the food pro-
vided during rearing on LCso values. A mixture of
pulverized dog biscuit and2o%o fish food or whole
cat pills (a type of compressed, protein-rich food
pellet) were compared.
All larvae were reared and tested at25--27"C. 12:
12 h light:dark (LD), except at Institut Pasteur and
Benzon Research where 14:10 h LD was used.
Bioassay: A quantity of the international stan-
dard IPS-82 was delivered to each participating lab-
oratory by Institut Pasteur. This standard is a ly-
ophilized powder containing 1.8-2.8 X 1011 spores/
g. The flowable product was provided by Novo-
Nordisk and contained.ca. 1 X 10to spores/g. The
product was formulated with a high level of glycol
and polyglycol to obtain a product that would not
freeze at -18'C. This product was intended to
serve as an internal standard at Novo-Nordisk. The
product was sealed in ampoules each containing 1.5
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g, and it was stipulated that at least one ampoule
should be used for each bioassay replicate. The lab-
oratories were asked to perform the bioassays ac-
cording to their usual routine and to describe this
routine in detail.
Institut Pasteur tested for interampoule variation
in the flowable sample by simultaneously testing 5
mixtures of 2 ampoules each, with 5 replicates us-
ing the same mixtures performed on 5 different
days. Novo-Nordisk performed 5 sets of bioassays
in 1 day to evaluate the intraday variation, and,26
other bioassays on different days using pairs of
standard and flowable samples. The other labora-
tories carried out I or 2 tests per day with a new
ampoule of flowable sample each day.
Some variation occurred in how samples were
processed. At Novo-Nordisk, 50 mg of the standard
IPS-82 were allowed to stand in water with a drop-
let of wetting agent (salt of polymer of carboxylate)
for 30 min, then homogenized and further diluted
to produce a series of test dilutions. Benzon Re-
search also added a wetting agent (O.27o Tween 80)
to the suspension before homogenizing. No other
laboratories used wetting agents. At all laboratories,
the flowable product was mixed with water to pro-
vide a stock from which other concentrations were
prepared. No other homogenization was necessary.
A summary of dilution and homogenization pro-
cedures is given in Table l.
None of the laboratories provided food during
the bioassays. Mortality was observed 24 h post-
treatment.
Raw data and protocols from each laboratory
were provided to the first author for analysis. Bio-
assay mortality data were log-probit transformed,
analyzed by linear regression, and the slope of the
transformed dose-mortality data was calculated. A
chi-square test was used for the validation of iter-
ative approaches to obtain the best fit of the re-
gression line (Finney l97I). A one-sided analysis
of variance (ANOVA) was carried out on each bio-
assay to evaluate goodness-of-fit to the probit mod-
el. Nonvalid tests were discarded (P > O.1O).
Finally potency of the flowable product was cal-
culated for each bioassay using the formula
LC..(Std)
potency(Fl) x potency(Std),
LL50( r r )
where Std is the international standard IPS-82 as-
signed a potency of 15,00O ITU/mg (de Barjac and
Larget-Thiery 1984) and Fl is the flowable test
product.
RESULTS
The calculated potency values of the flowable
B.r.l. product based on data provided by the 6 par-
ticipating laboratories are given in Table 2 and Fig.
1. The values range between 570 and 854 ITU/mg.
Some differences between laboratories are signifi-
cant, as noted (P < 0.01, df 5,88). The relatively
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large confldence limit of the ORSTOM mean value
was due to a low number of valid determinations
(5 compared to 12-27 from the other laboratories).
Potency is based on the ratio between the LCro
of the standard and the LCro of the flowable sample.
Therefore, the potency variations may be caused by
a variation in one or both parameters. Analysis of
variance showed the LCros of both products varied
significantly between laboratories (Table 2, p <<
O.OO1, df 5,97 for the test product; P << 0.001, df
5,74 for the standard). The LCro values from EID,
KABS, ORSTOM, and Institut Pasteur were nor
significantly different from each other. Benzon Re-
search obtained higher LCro values and Novo-Nor-
disk lower LCro values than the other 4 laboratories.
The slope of the dose-mortality curve of the
flowable product was significantly different than
that of the standard at Benzon Research, KABS.
and Novo-Nordisk (Table 3, p < 0.001) bur was
not significantly different at the other 3 laborato-
ries. The lack of difference at ORSTOM and Insti-
tut Pasteur may have been due to relatively low
replication. Where the slopes were different, the
slope of the flowable sample was higher than that
of the powder standard.
The EID laboratory compared the use of late 3rd
instars with early 4th instars. The LCro values of
the standard and the flowable sample were slightly(lOVo)blt not significantly higher using 4th instars(for the standard, P > 0.10, I : 0.89, df 15: for the
flowable sample, P > O.25, t : O.16, df 15). Ac-
cordingly, no differences were found in the potency
estimares (P > o.25, t : 0.ool2, df 15) or in the
slopes of the dose-mortality curves (ANOVA, ^P
<< O.OO1, F : 0.3, df 24).
When Institut Pasteur tested for interampoule
variation in the flowable sample, I of the 5 iepli-
cates was lost due to lack-of-fit in the standard.
Analysis of variance shows that no interaction oc-
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Benzon EID KABS Novo ORSTOM Pasteur
Fig. 1. Potency of a flowable Bacillus thuringiensis var. israelensis product as determined by 6 laboratories. Error
bars indicate standard deviations. Points labeled with the same letter are not significantly different (c : 0.05).
cured between s€rmple and test day (P > 0.05, F
: O.29, dt 4,12). Novo-Nordisk and Instirut pasteur
found greater variation in the LCro of the flowable
sample using results from all bioassays (the coef-
ficient of variation, defined as the quotient of the
standard deviation/mean : 22Vo for both labs) than
from multiple bioassays performed on the same day
(coefficient of variation : 8Vo for both labs). The
coefficients of variation for the LCro of the standard
on different days were 33 and 4OVo, respectively.
At the Novo-Nordisk laboratory, the type of food
provided to larvae during pretest rearing affected
both the LCro and the slope of IPS-82. A mixture
of dog biscuit and fish flakes resulted in an LC.n of
0.0071 pglrnl water vs. 0.0O94 pglml warer (Table
4, P < 0.01, r-test) for cat pills. The slopes of the
dose-mortality curves were 3.81 and 2.27, respec-
tively (Table 4, P < 0.001, r-test). Data on the flow-
able product were not obtained in this test.
The time required for larvae to reach 4th instars
varied according to the provided diet. At Benzon
Research, where dessicated liver powder was used,
only 3 days were required. At Novo-Nordisk, using
less protein-rich dog biscuits, 7 days were required.
At most other laboratories, using cat pills, 5-Z days
were required.
DISCUSSION
When potency bioassays were performed at 6
different laboratories on identical samples of a
flowable B.r.i. product, the results were not consis-
tent. Significant differences were found in the es-
timated potencies (Fig. 1 and Table 2) and in LCros
of both the flowable product and the international
standard IPS-82 (Table 2). Between laboratories,
the variation in the LCro was greater for the stan-
dard than for the flowable product (Table2). Within
laboratories, the variation in the LCro of the stan-
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dard was larger than that of the flowable prduct.
Accordingly, most variations found in potency de-
terminations were due to variation in the LCrn of
the standard. Most laboratories with a high number
of bioassay replicates showed a signiflcantly steep-
er slope in the dose-response curve for the flowable
product than for the standard.
Many explanations are possible for these inter-
laboratory differences. Although a thorough ex-
amination of the factors involved was beyond the
scope of this study, certain differences in methods
and materials were influential. For instance, given
the demonstrated influence of particle size on slope
(Skovmand et al. 1997), we would expect that the
method of homogenization of the IPS-82 powder
would influence slope. The powder consists of ag-
gregates of B.t.i. spores and crystals, and intense or
prolonged homogenization decreases the median
particle size. Homogenization would not influence
slope of the flowable product, as it was formulated
at the single celycrystal level and could not be di-
vided further. When stored in afreezet. the flowable
product would not increase in particle size because
it was formulated with a high level of antifreeze
agent and tested for nonfreezing characteristics.
Table 1 gives details on sample preparation and
handling for each laboratory. Tlvo laboratories used
high-speed rotor/stator rod homogenizers but with
different treatment times. Novo-Nordisk, using a
short treatment time of 30 sec, reported a significant
difference in slope between the flowable product
and the standard. The EID laboratory, using a long
treafinent time of 1O min, did not flnd a significant
difference. Novo-Nordisk analyzed actual particle
size distributions, and found that the volume me-
dian diameter of particles was 1.5 pm for the flow-
able product, and that the standard exhibited a bi-
modal distribution with one peak at 1.5 pm and
another larger peak at 15 pm (Skovmand et al.
1997). We believe that duration of homogenization
at EID reduced the larger aggregates of particles,
resulting in a size distribution more like that of the
flowable product. The other laboratories homoge-
nized sarnples by introducing glass beads into a
suspension and rotating on a shaker table or similar
device for between 5 and 30 min. This method pro-
vides relatively little shearing action and serves
mainly to break up large aggregates. TWo of the
laboratories using this method, Benzon Research
and KABS, obtained significant differences in slope
between mortality curves of the powder standard
and flowable sample.
Substantial variation may occur in the degree to
which particle size reduction occurs even when ef-
forts are made to standardize the method of ho-
mogenization. If this is true, we would expect that
the LCros and slopes of IPS-82 powder would ex-
hibit more within-laboratory variation than for the
flowable product. This was indeed the case at all
laboratories.
A significant correlation was found between the
Ssrrelrsen 1998 B.rr Potency: Interlaboratory Variations
Table 4. Influence of larval rearing food on the median lethal concentration (LC,o) and slope of dose-mortality
curve for the standard IPS-82.
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Dog biscuit * fish
flakes (z : 12)
Cat pills
( n : 5 )
Level of
significancel
LC5o + SD
Slope + SD
0.0071 + 0.0026
3.81 + 0.70
0.0094 + 0.0021
2.27 + l .Ol
P < 0.01
P < 0.001
I Studeni t-test for comparison between fmd regimes.
slope of the standard and that of the flowable sam-
ple across laboratories (Table 3, P < 0.05, df 4, ,.a
: 0.88). This indicates that slope is not only influ-
enced by particle size and other factors related to
the product, but by bioassay parameters such as ho-
mogeneity of test larvae. The test at EID did not
show significant differences in susceptibility or
slope between late 3rd and early 4th instars, so a
few 3rd instars in the test cups that are supposed
to contain only 4th instars should not materially
affect the results of bioassay. However, Benzon Re-
search reported that using 30-50Vo 3rd instars in
that laboratory reduces the LCro by 2O-3OVo com-
pared to using 1007o early 4th instars, but that po-
tency determinations were not significantly affected(unpublished data).
The different strains used for these bioassays
could not explain variations in slope, because OR-
STOM and KABS, with the lowest slope values,
and EID and Institut Pasteur, with much higher val-
ues, used the same strain originating from Institut
Pasteur, Ae. aegypti sfrain bora bora. However, the
LC.o may have been influenced by the mosquito
strain used. The 4 laboratories using strun bora
bora obtained similar LC.os (Table 2). The 2labo-
ratories using other strains found significantly dif-
ferent LCros. De Barjac and Coz (1979) showed that
t}re bora bora strain was less susceptible to B,t.i.
0.(),l5
0.0,10
0.fixt
than were various other strains tested at the same
laboratory. We have not determined whether our
results are due to use of the same strain or because
the 4 laboratories using the bora bora strur^ all
reared their larvae to test size within 5-6 days us-
ing very similar rearing methods.
A correlation was found between the number of
days required to reach 4th instars and the LCro
across laboratories (Fig. 2). This correlation may
be caused by rearing densities and feeding condi-
tions. Benzon Research provided protein-rich liver
powder in quantities such that food was never de-
pleted. This resulted in a development time of just
3 days. Novo-Nordisk used a carbohydrate-rich dog
biscuit mixture in relatively low quantities, result-
ing in a development time of 7 days. A more pro-
tein-rich diet (cat pills or liver powder) possibly
results in mosquito larvae that search less for bac-
teria during the test period, or are less susceptible
to the toxins than those fed smaller quantities of
less protein-rich diet. Dog biscuits contain much
fibrous matter resulting in larvae defecating mostly
undigested food wrapped in the peritrophic mem-
brane. Tests at Novo-Nordisk compared results of
bioassays using larvae that were reared on 2 dif-
ferent diets (Table 4). The LCro was higher and the
slope was lower when the test larvae were fed cat
.9
G
'
E o.oisg
oto()
0.010
f =O.87
d f = 4
P < 0.01
D,evclopment Tlmc to 4th lnstar
Fig. 2. Median lethal concentration (LCro) of the standard IPS-82 vs. larval age at the start of bioassays.
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pills compared to larvae fed with a mixture of dog
biscuit and fish flakes.
Novo-Nordisk and Institut Pasteur examined the
variation in LCro for multiple bioassays performed
on the same samples on the same day vs. different
days. Both laboratories obtained a coefficient of
variation of 8Vo for same-day bioassays and 22Vo
for different-day bioassays. These results support
the standard protocol recommendation that bioas-
say replicates should be carried out on different
days.
Much of the bioassay data obtained by OR-
STOM and some from KABS were discarded due
to insufficient numbers of observations between 0
and lNVo mortality. These laboratories used a di-
lution factor of 0.5 (i.e., each concentration used
was 0.5 times the next higher concentration) that
often resulted in more than one observation of 07o
andlor IOOVo mortality. The standard protocol rec-
ommends a dilution factor between 0.75 and 0.80.
which is more suitable for the slope of dose-mor-
tality curves found with most B.t i. products.
Overall. deviations from the WHO and U.S. De-
partment of Agriculture standard protocols with re-
gard to larval stage, holding temperature, and light-
ing regime, may not be as important as differences
in pretest rearing conditions. Variation in rearing
protocols were thought to affect the reference stan-
dard and the tested products equally (de Barjac
1985), but our results refute this.
We conclude that a standard test protocol should
specify larval rearing conditions such as type of
food and feeding schedule, larval density (such as
that suggested by de Barjac and Larget-Thiery
1984), sample treatment methods, the size of bio-
assay cups, and the density of larvae in each cup.
The latter parameter was shown to be important by
several authors (Mulla et al. 1990, Becker et al.
1992). For sample treatment, several possibilities
exist. Samples may all be homogenized to the sin-
gle-cell level to reduce variation between labora-
tories and product types, but the influence of this
treatment will be greater for some products (such
as powders) than for others. As an alternative, 2
standards may be used: a flowable standard with
flowable products and a powder standard with pow-
der products or products produced with powders,
for example, most granules. This, however, may
contribute to a general confusion about the meaning
and value of bioassays. The 2 standards would have
to be intercalibrated by a nonbioassay method.
Biochemical or irnmunologic methods have been
developed to assay crystal protein concentration
(Skovmand and Sterndort 1994). Thus far, such
tests have failed to provide a reliable correlate to
killing power and are incapable of determining the
bioavailability of toxin (e.g., particle size for mos-
quito larvae) or to distinguish between active and
inactive protein. The latter problem may be solved
with development of more specific methods, but the
problem of bioavailability is unlikely to be solved
by biochemical means. On the other hand, chemical
pesticides are labeled with the concentrations of ac-
tive ingredients, even though differences in for-
mulation can have a major impact on efficacy given
the same concentration of active ingredient. This
problem is mostly solved by specifying an appro-
priate field application rate. Such information is al-
ready required on a pesticide label whether the
prduct is chemical or microbial.
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